Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00064246 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder | completed | Phase 1 / Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00089271 | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077155 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00086944 | Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098891 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00401804 | Bortezomib-Dexamethasone-Doxorubicin-Study | completed | Phase 2 | 72 | Austrian Forum Against CancerOTHER | 2 | Jan 24, 2013 | clinicaltrials |
| NCT00005950 | 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00006473 | Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00777738 | Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia(WM2) | completed | Phase 2 | 34 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT01345357 | Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma | completed | Phase 1 | 24 | CephalonINDUSTRY | 2 | Jan 18, 2013 | clinicaltrials |
| NCT00036855 | Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00028821 | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00030381 | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00047203 | Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00363272 | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT01606605 | Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma | completed | — | 350 | Samsung Medical CenterOTHER | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00101244 | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00003166 | Bryostatin and Vincristine in B-Cell Malignancies | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00058305 | Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00891072 | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2013 | clinicaltrials |
| NCT01234974 | IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus | withdrawn | Phase 2 | 0 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 10, 2013 | clinicaltrials |
| NCT00017381 | Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma | completed | Early Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00335348 | Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse | completed | Phase 2 | 101 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00022581 | Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00118170 | Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function | completed | Phase 1 | 150 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00124605 | Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00253578 | Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00301795 | Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | terminated | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2013 | clinicaltrials |
| NCT00902525 | Zevalin Twice in Aggressive Non-Hodgkin Lymphoma | terminated | Phase 2 | 25 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieOTHER | 1 | Dec 31, 2012 | clinicaltrials |
| NCT00142181 | Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia | completed | Phase 2 | 27 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2012 | clinicaltrials |
| NCT00850499 | Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab | terminated | Phase 2 | 12 | Millennium Pharmaceuticals, Inc.INDUSTRY | 7 | Dec 12, 2012 | clinicaltrials |
| NCT00541424 | Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 6, 2012 | clinicaltrials |
| NCT01716364 | Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome | unknown | Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | terminated | Phase 2 | 20 | David RizzieriOTHER | 1 | Nov 28, 2012 | clinicaltrials |
| NCT00882063 | Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Piramal Enterprises LimitedINDUSTRY | 1 | Nov 21, 2012 | clinicaltrials |
| NCT00513175 | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | completed | — | 44 | University of California, San FranciscoOTHER | 1 | Nov 9, 2012 | clinicaltrials |
| NCT00366275 | Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma | completed | Phase 2 | 64 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00012350 | Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma | completed | Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 23, 2012 | clinicaltrials |
| NCT01409148 | Radioimmunoimaging of AL Amyloidosis | completed | Phase 1 | 38 | University of TennesseeOTHER | 1 | Oct 11, 2012 | clinicaltrials |
| NCT00920855 | Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | CephalonINDUSTRY | 1 | Oct 4, 2012 | clinicaltrials |
| NCT01700608 | Prospective Observational Study on Plerixafor After Chemotherapy | completed | — | 27 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 4, 2012 | clinicaltrials |
| NCT01054781 | Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL) | completed | Phase 2 | 91 | Samsung Medical CenterOTHER | 1 | Sep 27, 2012 | clinicaltrials |
| NCT00992134 | Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma | completed | Phase 2 | 41 | St. Bortolo HospitalOTHER | 1 | Sep 26, 2012 | clinicaltrials |
| NCT00005624 | CI-994 in Treating Patients With Advanced Myeloma | completed | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2012 | clinicaltrials |
| NCT00209222 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | unknown | Phase 3 | 360 | European Mantle Cell Lymphoma NetworkOTHER | 3 | Sep 10, 2012 | clinicaltrials |
| NCT01198457 | Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment(BONA) | completed | — | 147 | BayerINDUSTRY | 1 | Sep 7, 2012 | clinicaltrials |
| NCT01269203 | Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 7, 2012 | clinicaltrials |
| NCT00710528 | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 192 | Gilead SciencesINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study | terminated | Phase 1 / Phase 2 | 39 | Emory UniversityOTHER | 1 | Aug 30, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jan 25, 2013source: clinicaltrials